You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
A changing paradigm in the management of patients with severe aortic stenosis, transcatheter aortic valve implantation (TAVI) is a minimally invasive, catheter-based procedure to replace the aortic valve. Prior to TAVI, treatment options were limited to:
TAVI does not require open-heart surgery. Instead, with TAVI, the heart is accessed via an artery. There are three access options:
Using imaging and a delivery system, the physician threads the compressed bioprosthetic heart valve through the catheter and positions it within the diseased valve.
After positioning the bioprosthetic valve, the physician begins deploying the valve; the middle image below shows a partially expanded valve. When deployment is complete, the bioprosthetic valve is fully expanded within the diseased native valve.
After testing the new valve function, the physician removes the catheter and closes the incision.
TAVI may be an excellent option for certain patients with severe symptomatic aortic stenosis who may have increased risks associated with surgical aortic valve implantation (SAVI).1
Without intervention, this patient population's survival rate is approximately 50% at two years.2
The Evolut™ TAVI Platform is the only TAVI platform on the market to demonstrate statistically significant better outcomes in terms of all cause mortality or stroke at 3 years vs. SAVR.3
The Evolut TAVI platform’s supra-annular valve design delivers large EOAs (effective orifice area) and low single-digit gradients resulting in industry-leading hemodynamics.
Most medical procedures have risks. The Medtronic TAVI procedure’s most serious risks include:
Today, TAVI is a proven procedure that can prolong lives. At Medtronic, we believe it is the choice for patients who can return to an active life.
We've designed the Evolut platform to achieve industry-leading hemodynamics, which are important to younger, more active patients.
We offer outstanding training and resources for your heart teams.
Schwartz F, et al. Circulation. 1982; 66:1105-1110.
Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The natural history and rate of progression of aortic stenosis. Chest. 1998 Apr;113(4):1109-14. Review. PubMed PMID: 9554654.
Deeb GM, et al, J Am Coll Cardiol. 2016 Jun 7;67(22):2565-74. doi: 10.1016/j.jacc.2016.03.506. Epub 2016 Apr 3.